Publication

<2008年>

1. Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, Yusa K. Neutralizing antibodies decrease the envelope fluidity of HIV-1. Virology 37: :142-50. 2008

2. Maeda Y, Yusa K, Harada S. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res 77 :128-35, 2008

<2007年>

1. Monde K, Maeda Y, Tanaka Y, Harada S, Yusa K. Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5. J Biol Chem 282 :36923-32. 2007

2. Kumagai E, Tominaga M, Nagaishi S, Harada S. Effect of electrical stimulation on human immunodeficiency virus type-1 infectivity. Appl Microbiol Biotechnol 77: 947-53, 2007

3. Harada S, Yokomizo K, Monde K, Maeda Y, Yusa K. A broad antiviral neutral glycolipid, fattiviracin FV-8, is a membrane fluidity modulator Cell Microbiol 9: 196-203, 2007

<2006年>

1. Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20: 2065-73, 2006

<2005年>

1.Harada S. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem J 392: 191-9, 2005

2. Yusa K, Maeda Y, Fujioka A, Monde K, Harada S. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280: 30083-90, 2005

3. Harada S, Yusa K, Monde K, Akaike T, Maeda Y. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem Biophys Res Commun 329: 480-6, 2005

<2004年>

1. Song W, Maeda Y, Tenpaku A, Harada S, Yusa K. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations. Antiviral Res 61: 173-80, 2004

2. Harada S, Yusa K, Maeda Y. Heterogeneity of envelope molecules shown by different sensitivities to anti-V3 neutralizing antibody and CXCR4 antagonist regulates the formation of multiple-site binding of HIV-1. Microbiol Immunol 48:357-65, 2004

3. Harada S, Akaike T, Yusa K, Maeda Y. Adsorption and infectivity of human immunodeficiency virus type 1 are modified by the fluidity of the plasma membrane for multiple-site binding. Microbiol Immunol 48: 347-55, 2004

4. Kumagai E, Tominaga M, Harada S. Sensitivity of chronically HIV-1 infected HeLa cells to electrical stimulation. Appl Microbiol Biotechnol 63: 754-8, 2004

5. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 10: 4055-64, 2004

<2003年>

1. Maeda Y, Yusa K, Harada S.　Enhanced infectivity of HIV-1 by X4 HIV-1 coinfection.　Biochem Biophys Res Commun 308: 906-13, 2003

2.Tominaga M, Kumagai E, Harada S. Effect of electrical stimulation on HIV-1-infected HeLa cells cultured on an electrode surface. Appl Microbiol Biotechnol 61: 447-50, 2003

<2002年>

1. Harada S. Human immunodeficiency virus type 1 neutralization by a single molecule of V3-targeted antibody. Microbiol Immunol 46: 857-62, 2002

2. Yusa K, Song W, Bartelmann M, Harada S. Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors. J Virol 76: 3031-7, 2002

<2001年>

1. Tempaku A, Maeda Y, Song W, Harada S. Human T-cell leukemia virus type-I (HTLV-I) tax is not the only one factor to enhance human immunodeficiency virus type-I (HIV-1) infection in culture-supernatants. Virus Genes 23: 77-80, 2001

.2. Foda M, Harada S, Maeda Y. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol Immunol 45: 521-30, 2001

3. Song W, Yahara S, Maeda Y, Yusa K, Tanaka Y, Harada S. Enhanced infection of an X4 strain of HIV-1 due to capping and colocalization of CD4 and CXCR4induced by capsianoside G, a diterpene glycoside. Biochem Biophys Res Commun 283 :423-9, 2001